Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01346163 · ClinicalTrials.gov registry record · Phase 1

Add On Treatment for Cognitive Deficits in Schizophrenia

A Phase 1 study of Schizophrenia, sponsored by University of Pennsylvania.

Completed
Registry status
Phase 1
Development phase
16
Enrollment target
1
Study location

NCT01346163 is a Phase 1 study of Schizophrenia that has completed, run by University of Pennsylvania. The registered enrollment target is 16 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01346163, a Phase 1 study of Schizophrenia, has completed, sponsored by University of Pennsylvania.

COMPLETED
Registry status
Phase 1
Development phase
16 participants
Enrollment target
1
Study location

Study Summary

This study will look at the impact of dosing as well as ongoing treatment with an investigation medication identified as PF-03654746, on cognitive and physiologic indicators of brain function. Data from this study will assist with the evaluation of the utility of functional magnetic resonance imaging, arterial spin labeling (ASL), and electrophysiologic measures in the detection of early signals of the effectiveness of medications developed to target cognitive impairment in schizophrenia. Safety and tolerability of PF-03654746 in this population will be also be evaluated.

Conditions Studied

Schizophrenia

Interventions

  • OTHER Placebo
  • DRUG PF 03654746

Study Locations (1)

Pennsylvania

  • University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2009-04
Est. Completion 2010-11
Phase Phase 1

Sponsor

University of Pennsylvania

1,423 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01346163

The ClinicalTrials.gov registry entry for NCT01346163 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (93% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01346163 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT01346163 about?

NCT01346163 is a clinical study titled "Add On Treatment for Cognitive Deficits in Schizophrenia". This study will look at the impact of dosing as well as ongoing treatment with an investigation medication identified as PF-03654746, on cognitive and physiologic indicators of brain function. Data from this study will assist with the evaluation of the utility of functional magnetic resonance imagin...

What is the current status of trial NCT01346163?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2009-04. Estimated completion is 2010-11.

What conditions does trial NCT01346163 study?

This clinical trial studies the following conditions: Schizophrenia.

What interventions are being tested in trial NCT01346163?

The interventions under investigation include: Placebo (OTHER), PF 03654746 (DRUG).

Who is sponsoring clinical trial NCT01346163?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01346163 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Schizophrenia

All registered trials for this condition

Pennsylvania

All trials with a study site in Pennsylvania

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.